Talaris Therapeutics Inc Aktie News

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Tourmaline Bio, Inc. (NasdaqGS: TRML) to Novartis AG. Under the terms of the proposed transaction, shareholders of Tourmaline will receive $48.00 in cash for each share of Tourmaline that they own....

Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, i...

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Tourmaline Bio, Inc. (NasdaqGS: TRML) to Novartis AG. Under the terms of the proposed transaction, shareholders of Tourmaline will receive $48.00 in cash for each share of Tourmaline that they own....

Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis (NVS) is buying the small biotech firm for $1.4 billion to complement its cardiovascular pipeline is giving Tourmaline a fresh boost.

Shares of Tourmaline Bio surged in premarket trading on Tuesday after the US-based biotechnology company agreed to be acquired by Swiss pharmaceutical major Novartis for approximately $1.4 billion. Tourmaline shares jumped nearly 58%, trading at $48 per share, compared with Monday's closing price of $30.18.

Nebius surges 49% pre-market after securing a $17.4B AI infrastructure deal with Microsoft, potentially expanding to $19.4B. Novartis acquires Tourmaline Bio for $1.4B in cash, a 59% premium, highlighting confidence in Tourmaline's cardiovascular drug pipeline.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Tourmaline Bio, Inc. (NASDAQ: TRML) to Novartis AG for $48.00 per share in cash is fair to Tourmaline shareholders. Halper Sadeh encourages Tourmaline shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-00...

Novartis AG (ADR) (NYSE:NVS) has agreed to buy Tourmaline Bio in a $1.4 billion cash deal, strengthening its push into cardiovascular medicine with a late-stage anti-inflammatory drug candidate. The Swiss pharmaceutical group will pay $48.00 a share, a 59% premium to Tourmaline's closing price on Monday and 127% above its 60-day average.